FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

Figure 1 Kaplan-Meier curves of overall survival and progression-free survival for the FOLFIRINOX and FOLFOXIRI groups in the overall population and the propensity score‐matched population. A: Overall survival in the whole population; B: Progression-free survival in the whole population; C: Overall survival in the propensity score-matched population; D: Progression-free survival in the propensity score-matched population. P < 0.05 from the log-rank test was considered statistically significant, and all tests were two-sided. CI: Confidence interval; HR: Hazard ratio.